Cohance Faces USFDA Observations at Telangana Plant

Cohance Lifesciences is in focus after the USFDA completed an inspection of its Shamshabad formulation facility in Telangana. The inspection, conducted from August 27 to September 4, 2026, concluded with four observations issued through Form FDA 483. The company said it has initiated corrective and preventive actions (CAPA) and will submit its response to the regulator within the stipulated timeline. The observations could remain a near-term overhang until the company addresses the regulatory concerns. Separately, Cohance has announced a strategic investment of $18 million in NJ Bio and Aruka Bio to strengthen its antibody-drug conjugate (ADC) capabilities. The investment is aimed at expanding its global CRDMO platform and integrated ADC offerings. Investors will now track the company’s response to the USFDA observations along with the progress of its ADC expansion strategy. Successful remediation and execution of new investments could support long-term growth, while regulatory developments remain a key near-term factor for the stock.